RNA-based therapeutics demand high-resolution quality control to ensure safety, efficacy, and consistency.

In this GEN webinar, Wayne Doyle will showcase how Eclipsebio’s eMERGE platform leverages nanopore sequencing to directly measure critical quality attributes—including base identity, poly(A) tail length, RNA integrity, and secondary structure within lipid nanoparticles. Learn how integrating sequencing-driven insights across development and manufacturing can reduce risk and strengthen confidence as RNA programs advance toward the clinic. Key takeaways from the webinar are:

• How nanopore sequencing enables high-resolution measurement of critical quality attributes (CQAs), including base identity, poly(A) tail length, and RNA integrity.
• How Eclipsebio’s sequencing-first eMERGE platform integrates nanopore and complementary assays to characterize RNA quality, from sequence fidelity and fragmentation to structural features and impurity profiling.
• How embedding sequencing-driven quality analytics into development and manufacturing workflows strengthens product understanding, improves batch-to-batch consistency, and reduces risk across the RNA therapeutic lifecycle.

A live Q&A session followed the presentations, offering a chance to pose questions to our expert panelists.

Produced with support from: